InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
winningpenny Terminated
10/25/22 10:52 PM
profile icon
mrsdoubtfire Free
10/21/22 11:44 PM
profile icon
pdgood Free
05/30/22 2:01 PM
profile icon
Kool Aid Man Free
05/19/22 5:32 PM
profile icon
Thugmuffin Free
05/15/22 5:26 AM
profile icon
Kool Aid Man Free
05/10/22 6:19 PM
profile icon
Thugmuffin Free
03/05/22 8:19 AM
profile icon
AskMuncher Free
02/19/22 8:26 AM
profile icon
tocatchu Free
04/29/21 4:33 PM
profile icon
StockTrade22 Free
04/16/21 1:52 PM
profile icon
makinezmoney Free
04/15/21 9:18 AM
profile icon
Renee PremiumMember
04/15/21 6:42 AM
profile icon
StockTrade22 Free
03/18/21 3:26 PM
profile icon
StockTrade22 Free
03/10/21 10:36 AM
profile icon
StockTrade22 Free
03/10/21 10:33 AM
profile icon
Kennyjo Free
03/09/21 6:45 PM
profile icon
Midwestrader Free
03/09/21 4:21 PM
profile icon
Kool Aid Man Free
03/01/21 7:28 PM
profile icon
StockTrade22 Free
02/26/21 2:17 PM
profile icon
StockTrade22 Free
02/19/21 8:21 PM
profile icon
shanak10 Free
02/04/21 8:49 AM
profile icon
StockTrade22 Free
01/07/21 10:37 AM
profile icon
Kool Aid Man Free
11/20/20 3:49 PM
profile icon
shanak10 Free
11/20/20 2:15 PM
profile icon
mrsdoubtfire Free
11/20/20 2:09 PM
profile icon
mrsdoubtfire Free
11/20/20 12:20 PM
profile icon
shanak10 Free
11/20/20 10:57 AM
profile icon
LINK Oracle Free
11/12/20 3:50 PM
profile icon
shanak10 Free
11/05/20 9:14 AM
profile icon
Midwestrader Free
10/25/20 2:31 PM
profile icon
StockTrade22 Free
10/23/20 10:56 AM

Stella Diagnostics Inc (SLDX) RSS Feed

Followers
584
Posters
Posts (Today)
0
Posts (Total)
187251
Created
05/15/07
Type
Free
Moderators

Stella Diagnostics, Inc. (OTC: SLDX) is a molecular diagnostics-based organization focused on improving patient management strategies for over 60 million people living with severe esophageal disease. Stella Diagnostics’ clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives.

Currently, Stella Diagnostics has four tests in the pre-commercialization development stage. Each test is based on different sets of biomarkers. The STLA101 panel consists of novel biomarkers that may be predictive of carcinogenesis in precancerous esophageal tissue. STLA102 consists of biomarkers associated with increased efficacy of resistance to all of the FDA approved chemotherapies and targeted therapies for esophageal adenocarcinoma. The STLA103 panel detects and quantifies proliferation markers discovered and published by Abdo, et al (2015) in which expression trends of these markers would be indicative of rampant cellular multiplication which is a molecular hallmark of cancer. The STLA104 panel detects and quantifies cell-death markers discovered and published by Abdo, et al (2015) in which expression trends of these biomarkers assess a decline in programmed-cell death or apoptosis which can be another hallmark of carcinogenesis. For more information, please visit www.stelladx.com.



Stella Diagnostics (SLDX): Providing Insight into Esophageal Disease

              

Stella Diagnostics (SLDX) Investor Deck





 


Stella Diagnostics, Inc. | 50 West Broadway, Suite 300 | Salt Lake City, UT 84104 | info@stelladx.com | 1-201-381-1474 | www.stelladx.com  
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
SLDX Latest News
  • No Recent News Available for this company!
New Post